WBA - Walgreens Boots Alliance, Inc.
| Previous Close | 72.43 |
| Open | 72.12 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 4000 |
| Day's Range | 71.11 - 72.29 |
| 52 Week Range | 59.07 - 86.31 |
| Volume | 5,578,261 |
| Avg. Volume | 6,615,625 |
| Market Cap | 67.541B |
| Beta (3Y Monthly) | 0.86 |
| PE Ratio (TTM) | 13.17 |
| EPS (TTM) | 5.44 |
| Earnings Date | Mar 26, 2019 - Apr 1, 2019 |
| Forward Dividend & Yield | 1.76 (2.44%) |
| Ex-Dividend Date | 2018-11-08 |
| 1y Target Est | 76.26 |
- The Wall Street Journal•4 hours ago
[$$] Walgreens to Pay $269 Million on Claims It Overcharged Federal Programs
Walgreens Boots Alliance Inc. has agreed to pay more than $269 million to settle federal and state lawsuits that accused it of overbilling federal health-care programs. Two separate settlements involving Walgreens, approved last week by U.S. District Court judges in Manhattan, were unsealed Tuesday, according to the U.S. Justice Department. In the first settlement, Walgreens agreed to pay $209.2 million to the U.S. and several state governments for improperly billing Medicare, Medicaid and other federal health-care programs for hundreds of thousands of insulin pens it dispensed to program beneficiaries who didn’t need them, according to U.S. officials.
- Reuters•8 hours ago
Walgreens pays $269.2 mln to settle U.S. civil fraud lawsuits
Walgreens Boots Alliance Inc will pay $269.2 million to settle two whistleblower lawsuits accusing it of civil fraud for overbilling federal healthcare programs over a decade, the U.S. Department of Justice said on Tuesday. The pharmacy chain will pay $209.2 million to resolve claims it improperly billed Medicare, Medicaid and other federal programs from 2006 to 2017 for hundreds of thousands of insulin pens it dispensed to patients it knew did not need them. Walgreens will also pay $60 million to resolve claims it overcharged Medicaid from 2008 to 2017 by failing to disclose and charge the discount drug prices it offered the public through its Prescription Savings Club program.
- Market Realist•10 hours ago
Will Walgreens’s Strategic Initiatives Boost Its Sales?
How Is Walgreens Boots Alliance Positioned in 2019?(Continued from Prior Part)Sales growth trend Walgreens Boots Alliance’s (WBA) sales rose 9.9% to $33.8 billion in the first quarter of fiscal 2019 (which ended on November 30, 2018) driven by its
- Reuters•10 hours ago
U.S. recovers $269.2 mln in Walgreens civil fraud settlements
Walgreens Boots Alliance Inc will pay $269.2 million to the United States and state governments to settle two civil healthcare fraud lawsuits, the U.S. Department of Justice said on Tuesday. The Justice Department said Walgreens will pay $209.2 million to resolve claims it improperly billed Medicare, Medicaid and other federal programs for unnecessarily dispensing hundreds of thousands of insulin pens, and $60 million to resolve claims it overbilled Medicaid by concealing lower drug prices it offered the public through a discount program.
- Market Realist•11 hours ago
How Is Walgreens Boots Alliance Positioned in 2019?
How Is Walgreens Boots Alliance Positioned in 2019?WBA’s movements so far in 2019 As of January 18, Walgreens Boots Alliance (WBA) stock has risen 6.0% since the start of 2019. In comparison, the stock of its closest rival, CVS Health (CVS), is
- Markit•19 hours ago
See what the IHS Markit Score report has to say about Walgreens Boots Alliance Inc.
# Walgreens Boots Alliance Inc ### NASDAQ/NGS:WBA View full report here! ## Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding ## Bearish sentiment Short interest | Positive Short interest is low for WBA with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $1.33 billion over the last one-month into ETFs that hold WBA are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Positive According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Services sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- MoneyShow•22 hours ago
Top Picks 2019- Walgreens Boots WBA
Walgreens Boots (WBA) has fallen in recent trading to a point that makes these shares especially attractive for 2019, asserts dividend reinvestment specialist Chuck Carlson, editor of the industry-leading DRIP Investor.
- Business Wire•2 days ago
Walgreens Boots Alliance to Webcast Annual Meeting of Stockholders
Walgreens Boots Alliance, Inc. (WBA) will provide a live webcast of its annual meeting of stockholders beginning at 8:30 a.m. EST on Friday, January 25, 2019. The meeting's webcast will be available through the Walgreens Boots Alliance investor relations website at: http://investor.walgreensbootsalliance.com. Cautionary Note Regarding Forward-Looking Statements: All statements in this release and related stockholder meeting and webcast that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
- Motley Fool•3 days ago
Microsoft Tethers Another Major Retailer to Its Cloud
Walgreens joins Microsoft’s growing list of “anti-Amazon” cloud customers.
- Zacks•4 days ago
Walgreens (WBA) Up 4.1% Since Last Earnings Report: Can It Continue?
Walgreens (WBA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Motley Fool•4 days ago
Better Buy: Walgreens Boots Alliance vs. CVS Health
You might know which pharmacy you prefer, but which stock is best for your portfolio?
- Zacks•4 days ago
Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
Walgreens Boots Alliance (WBA) closed the most recent trading day at $72.30, moving +0.43% from the previous trading session.
GuruFocus.com•5 days agoAnalysts Commence Coverage on Large Caps
Walgreens Boots Alliance and Adobe amid the top initiations
- Zacks•5 days ago
Dow 30 Stock Roundup: JPM & AXP Earnings Disappoint, GS & UNH Impress
The index enjoyed another strong week of gains, increasing over three straight sessions.
- Investopedia•5 days ago
How Walgreens Is Going to War Against Amazon
The U.S. pharmacy chain has partnered with two tech giants in an aggressive defensive battle against Amazon.
- TheStreet.com•6 days ago
Here Are 2 Ways to Play Microsoft Stock
By the way, the deal between MSFT and WBA is a seven year marriage that involves access to Windows 10, and Office 365 for more than 380K Walgreens employees while the firm migrates most of it's technology infrastructure onto the Azure platform. Walgreens is not alone.
- TheStreet.com•6 days ago
Earnings, the Fed, Government Shutdown,Trading Microsoft: Market Recon
Equity markets have come a long way since bottoming the day after Christmas. The central bank made an effort to calm the street in the wake of the December 19th Jerome Powell press conference. Trading volume, by the way had spiked on the 3rd, and has mostly tailed off since then.
- InvestorPlace•6 days ago
Walgreens, Already Late to the Party, Arrives Empty-Handed
News this week that drugstore chain Walgreens Boots Alliance (NASDAQ:WBA) and software behemoth Microsoft (NASDAQ:MSFT) are teaming up to inject some fresh tech into Walgreens stores brought cheers from investors. WBA stock holders were pleased, to be sure, knowing too well that the company hasn't kept up with rivals' business-building partnership development. Yet, as the celebration winds down, tough questions are starting to surface. Chief among them is, how exactly will this WBA-MSFT alliance bolster the bottom line? A close-second (and related) question is: how exactly will this partnership change the way consumers receive care? Maybe good answers will come in time, but as it stands right now, there are no answers at all. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### Just Another Partnership? The short version of a long story: Health care's a mess in America. Aside from being too expensive for consumers and too inefficient for all players, it's also often ineffective. The federal government has thus far been powerless to get a grip on any of those challenges. That's largely why we've seen a wave of M&A within the industry over the past several years -- players are doing what they can just to survive and still give decent care. That deal-making took on a whole new tone a year ago, however, when Amazon.com (NASDAQ:AMZN), JPMorgan Chase (NYSE:JPM) and Berkshire Hathaway (NYSE:BRK.A, NYSE:BRK.B) teamed up to develop their own kind of health care organization. The aim of this venture isn't to drive profits. The three organizations are partnering primarily to cull their own realized costs of providing health benefits for their employees. Nevertheless, the creation of an in-house solution was also an unspoken message that the nation's health care industry was no longer capable of doing what it should be able to do. Other less-shocking partnerships sent a similar message. CVS Health (NYSE:CVS) now owns insurer Aetna, crossing a line not all consumers/patients are sure they want crossed. Meanwhile, Humana (NYSE:HUM) and CVS have forged an alliance, of sorts. In fact, Aetna and Humana would now be the same company had the Justice department not put the kibosh on the deal. * 10 Growth Stocks With the Future Written All Over Them In that light, the Walgreens-Microsoft partnership looks and feels like the next natural progression of the industry. Owners of Walgreens stock, however, may want to take a closer look at the deal… not so much at what was said, but wasn't said. ### No Clear Plan For 7-Year Deal The precise plans for the team-up shouldn't be -- and arguably can't be -- disclosed, as it's unlikely even the companies themselves know what this seven-year deal will lead to seven years from now. Still, one would expect at least a bit more clarity on how the development will boost business. The key tenets of the deal include the use of Microsoft's office-productivity software by Walgreens employees, making self-care options available to patients (presumably through an app), and the reduction of friction between payers and providers. Some Walgreens stores will also, as a pilot program, dedicate floor space to sales of medical hardware and devices that (again, presumably) make the most out of the other improvements at-hand. It all sounds compelling. A second glance at the announcement, however, also reads like little more than a marketing brochure. The partnership's goals are also the same as those that every other player in the health care arena hopes to achieve. The question then becomes, how are Walgreens and Microsoft going to differentiate what they're going to do from the drug store operator's competitors? It's easy to say the aim is making self-care and prescriptions a seamless experience. Far more difficult is convincing consumers to use such a tool, and then teaching them to use it. Constant changes to health insurance policies only exacerbate the confusion that patients may not be able to address themselves, and Microsoft's role in Walgreens' push of new medical devices is fuzzy at best. Candidly, too, the deal also comes across a little bit desperate. Walgreens CEO Stefano Pessina initially said he wasn't worried about Amazon's 2018 acquisition of online pharmacy PillPack. "This partnership with Microsoft suggests otherwise," said drug supply chain expert Stephen Buck on Tuesday. Making deals from a have-to position is starkly different than want-to deals. And there's the rub. At this point, with most of the best potential partnerships already off the table, Walgreens' interest is in partnerships without an entirely clear purpose or meaningful plan. CVS wanted Aetna for obvious reasons, but also for less obvious reasons like leveraging CVS's pharmacy benefits management wing and using existing stores to build out a network of mini-clinics that will ultimately lower costs for all. Amazon, Berkshire and JPMorgan are just trying to save money. Cigna Holding (NYSE:CI) wanted Express Scripts so it could also gain control of its costs by controlling a pharmacy benefits manager. * 7 Stocks at Risk of the Global Smartphone Slowdown In contrast, the Microsoft partnership with Walgreens (as impressive as some of the technology rollouts may end up being) doesn't look like it will accomplish anything that Walgreens couldn't achieve with several other tech companies… whatever it ends up accomplishing. ### Bottom Line for Walgreens Stock Don't misread the message. The alliance isn't an ill-advised decision, nor will it end up crimping the value of WBA stock. Indeed, the two organizations may have something game-changing in mind that can't yet be divulged. It's more likely than not, however, that the team-up is no more and no less than it currently seems to be on the surface. That is, a modernization of the Walgreens IT infrastructure. It's a smart and necessary step, but it's not the game-changer the stores need if WBA aims to prevent more team-ups like the Amazon/Berkshire/JPMorgan partnership and CVS's in-house clinics from siphoning away customers. In that light, the far-less-touted work Walgreens is doing with Google's life-sciences arm Verily -- to better manage chronic illnesses -- offers more promise for real revenue creation. Even then though, it may not be enough to light a fire under WBA stock anytime soon. Edward Jones analyst John Boylan noted last month, before the Microsoft team-up was unveiled, "Many of these partnerships are still in their very early stages, and we would like to see if these services will have a notable impact on growth and profitability, and if its cost cutting efforts will counteract the continuing reimbursement pressure we are seeing in the drugstore market." Walgreens still needs something big, above and beyond the acquisition of rivals' stores, and it needs it sooner rather than later. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Top 10 Global Stock Ideas for 2019 From RBC Capital * 10 A-Rated Stocks the Smart Money Is Piling Into * 5 Best Bank ETFs for This Week's Earnings Avalanche Compare Brokers The post Walgreens, Already Late to the Party, Arrives Empty-Handed appeared first on InvestorPlace.
- Motley Fool•6 days ago
Walgreens Inks a Massive Deal With Microsoft
The pharmacy is joining a growing number of retailers snubbing rival Amazon.
- Zacks•7 days ago
Microsoft, WBA Deal to Break AMZN, GOOGL Healthcare Dreams
Microsoft (MSFT) inks a seven-year deal with Walgreens to offer innovative healthcare delivery solutions that can pose threat to Amazon and Google's growing presence.
- Business Wire•7 days ago
Nebraska, New Mexico and Kentucky Take Top Spots for State Flu Activity in this Week’s Walgreens Flu Index™
Lincoln, Nebraska and El Paso, Texas remain the top markets for flu activity
- Zacks•7 days ago
Amazon Fear Grips Retail Pharmacy Space, Alliances Continue
While Amazon is figuring out ways to expand in the multibillion dollar pharmacy industry, Walgreens and other industry players are ready to counter competition.
- Market Exclusive•7 days ago
Market Morning: Brexit Burn, New Anti-Cannabis AG, Cobalt On Blockchain, Microsoft on Healthcare
Brexit Deal Goes Down in Flames, Markets Yawn Theresa May’s Brexit deal was defeated by such a large margin, 432-202, that stock markets have been shocked into complacency over it, or at least that’s what it seems. With such a huge defeat, there is no way that the deal can be renegotiated or tweaked to […] The post Market Morning: Brexit Burn, New Anti-Cannabis AG, Cobalt On Blockchain, Microsoft on Healthcare appeared first on Market Exclusive.
- TheStreet.com•7 days ago
Microsoft Shares Up After Major Health Care Deal With Walgreens
that will explore new ways of delivering health care while also handing the tech giant hundreds of thousands of new users. Walgreens will move "the majority of the company's IT infrastructure" onto Microsoft Azure while also rolling out Microsoft 365 to the retailer's 380,000 employees around the world, according to a press release by Walgreens. Microsoft rose 2.90%, to close at $105.01, while Walgreens was up 1.61%, to $71.79.
